Enfermedades quísticas renales

Cornec-Le Gall, 2019, Autosomal dominant polycystic kidney disease, Lancet., 393, 919, 10.1016/S0140-6736(18)32782-X Grantham, 2008, Autosomal-dominant polycystic kidney disease, N Engl J Med., 359, 1477, 10.1056/NEJMcp0804458 Cornec-Le Gall, 2018, Genetic complexity of autosomal dominant polycystic kidney and liver diseases, J Am Soc Nephrol., 29, 13, 10.1681/ASN.2017050483 International Polycystic Kidney Disease Consortium, 1995, Polycystic kidney disease: the complete structure of the PKD1 gene and its protein, Cell., 81, 289, 10.1016/0092-8674(95)90339-9 Porath, 2016, Mutations in GANAB, encoding the glucosidase iialpha subunit, cause autosomal-dominant polycystic kidney and liver disease, Am J Hum Genet., 98, 1193, 10.1016/j.ajhg.2016.05.004 Cornec-Le Gall, 2018, Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease, Am J Hum Genet., 102, 832, 10.1016/j.ajhg.2018.03.013 Qian, 1999, Somatic mutation as mechanism or cyst formation in autosomal dominant polycystic kidney disease, Mol Genet Metab., 68, 237, 10.1006/mgme.1999.2896 Torres, 2006, Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases, Nat Clin Pract Nephrol., 2, 40, 10.1038/ncpneph0070 Chebib, 2016, Autosomal dominant polycystic kidney disease: Core curriculum 2016, Am J Kidney Dis., 67, 792, 10.1053/j.ajkd.2015.07.037 Grantham, 2006, CRISP Investigators. Volume progression in polycystic kidney disease, N Engl J Med, 354, 2122, 10.1056/NEJMoa054341 Chapman, 2012, Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease, Clin J Am Soc Nephrol., 7, 479, 10.2215/CJN.09500911 Chebib, 2018, A practical guide for treatment of rapidly progressive ADPKD with tolvaptan, J Am Soc Nephrol., 29, 2458, 10.1681/ASN.2018060590 Razabal, 2015, Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials, J Am Soc Nephrol., 26, 160, 10.1681/ASN.2013101138 Chapman, 2010, The HALT polycystic kidney disease trials: design and implementation, CJASN., 5, 102, 10.2215/CJN.04310709 Casteleijn, 2014, Chronic kidney pain in autosomal dominant polycystic kidney disease: a case report of successful treatment by catheter-based renal denervation, Am J Kidney Dis., 63, 1019, 10.1053/j.ajkd.2013.12.011 Peces, 2012, Tratamiento con ácido tranexámico de la hematuria incoercible en la poliquistosis renal autosómica dominante, Nefrologia., 32, 160 Fick-Brosnahan, 2002, Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study, Am J Kid Dis., 39, 1127, 10.1053/ajkd.2002.33379 Bernts, 2020, Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease, Surgery., 168, 25, 10.1016/j.surg.2020.02.014 Schrier, 2010, Randomized intervention studies in human polycystic kidney and liver disease, J Am Soc Nephrol., 21, 891, 10.1681/ASN.2010030262 Chapman, 1992, Intracranial aneurysms in autosomal dominant polycystic kidney disease, N Engl J Med., 327, 916, 10.1056/NEJM199209243271303 Torres, 2006, Water for ADPKD? Probably, Yes Water, J Am Soc Nephrol., 17, 2089, 10.1681/ASN.2006060603 Schrier, 2014, Blood pressure in early autosomal dominant polycystic kidney disease, N Engl J Med., 371, 2255, 10.1056/NEJMoa1402685 Torres, 2012, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med., 367, 2407, 10.1056/NEJMoa1205511 Torres, 2017, REPRISE trial investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease, N Engl J Med., 377, 1930, 10.1056/NEJMoa1710030 Sekine, 2022, Cystic kidney diseases that require a differential diagnosis from autosomal dominant polycystic kidney disease (adpkd), J Clin Med., 11, 6528, 10.3390/jcm11216528 Guay-Woodford, 2003, Autosomal recessive polycystic kidney disease: the clinical experience in North America, Pediatrics., 111, 1072, 10.1542/peds.111.5.1072 Bergmann, 2005, Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD), Kidney Int., 67, 829, 10.1111/j.1523-1755.2005.00148.x Gunay-Aygun, 2010, Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease, Clin J Am Soc Nephrol., 5, 972, 10.2215/CJN.07141009 Maher, 2011, von Hippel-Lindau disease: a clinical and scientific review, Eur J Hum Genet., 19, 617, 10.1038/ejhg.2010.175 Silverman, 2019, Bosniak classification of cystic renal masses, version 2019: An update proposal and needs assessment, Radiology., 292, 475, 10.1148/radiol.2019182646 Nielsen, 2016, Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome, J Clin Oncol., 34, 2172, 10.1200/JCO.2015.65.6140 Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat Rev Cancer., 15, 55, 10.1038/nrc3844 Bissler, 2018, Renal manifestation of tuberous sclerosis complex, Am J Med Genet C Semin Med Gene., 178, 338, 10.1002/ajmg.c.31654 Shillingford, 2006, The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease, Proc Natl Acad Sci USA., 103, 5466, 10.1073/pnas.0509694103 Kingswood, 2014, TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex, Orphanet J Rare Dis., 9, 182, 10.1186/s13023-014-0182-9 Kingswood, 2016, Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: Current data and future study, Nephron., 134, 51, 10.1159/000448293 Bissler, 2016, Long-term clinical morbidity in patients with renal angiomyolipoma associated with tuberous sclerosis complex, Urology., 95, 80, 10.1016/j.urology.2016.04.027 Malaga-Dieguez, 2017, Early manifestations of renal disease in patients with tuberous sclerosis complex, Int J Nephrol Renovasc Dis., 10, 91, 10.2147/IJNRD.S123638 Siroky, 2009, Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms, Nat Clin Pract Nephrol., 5, 143 Hong, 2013, What association exists between hypertension and simple renal cyst in a screened population, J Hum Hypertens., 27, 533, 10.1038/jhh.2013.12 Fleming, 2010, Renal cell carcinoma in acquired cystic kidney disease, Histopathology., 56, 395, 10.1111/j.1365-2559.2010.03492.x Kojima, 2020, Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions, Am J Surg Pathol., 44, 1031, 10.1097/PAS.0000000000001482 Torres, 2014, Strategies targeting cAMP signaling in the treatment of polycystic kidney disease, J Am Soc Nephrol., 25, 18, 10.1681/ASN.2013040398